Literature DB >> 16394618

The status of lipid management in 1,836 patients with coronary artery disease: a multicenter survey to evaluate the percentage of Japanese coronary artery disease patients achieving the target low-density lipoprotein cholesterol level specified by the Japan Atherosclerosis Society.

Hirotaka Nagashima1, Hiroshi Kasanuki.   

Abstract

To determine the status of lipid management in patients with coronary artery disease (CAD) in Japan, we assessed CAD patients who had been receiving lipid-lowering therapy for six months in a cross-sectional survey conducted between June 2001 and December 2002. We defined the achievement rate as the percentage of patients who achieved the target LDL-C level (< 100 mg/dl) specified by the Japan Atherosclerosis Society (JAS). A total of 1,836 Japanese CAD patients were enrolled. In total, 549 (29.9%) achieved the target level. The achievement rate among those receiving statin therapy was 41.3%, which was significantly higher than that (23.4%) among the patients not receiving statin (P < 0.0001). The rate differed with the type of statin; being 54.7% for atorvastatin, 24.8% for pravastatin, 37.1% for simvastatin, and 27.8% for fluvastatin. A multiple regression analysis revealed that atorvastatin use (P < 0.001), and simvastatin use (P = 0.004) significantly contributed to the achievement of the target LDL-C level. In conclusion, large proportions of CAD patients are not achieving the JAS target and the success rates are not similar among different statin therapies, suggesting that cardiologists should consider a more aggressive lipid-lowering therapy with the appropriate choice of statins in Japanese CAD patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16394618     DOI: 10.5551/jat.12.338

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  2 in total

1.  The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin.

Authors:  Zo Rakotoniaina; Pascal Guerard; Frederic Lirussi; Françoise Goirand; Luc Rochette; Monique Dumas; Marc Bardou
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-11-11       Impact factor: 3.000

2.  CEPHEUS SA: a South African survey on the undertreatment of hypercholesterolaemia.

Authors:  F Raal; C Schamroth; D Blom; J Marx; M Rajput; M Haus; R Hussain; F Cassim; M Nortjé; G Vandehoven; A-M Temmerman
Journal:  Cardiovasc J Afr       Date:  2011-09-15       Impact factor: 1.167

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.